Mouchun Gong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mouchun Gong has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Zhaoqing Jin
2 shared publicationsZiqiang Yang
2 shared publications- Changjun Chen
Department of Orthopaedic Surgery, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, People’s Republic of China
1 shared publication Chen Dailing
Department of Orthopaedics Surgery, Shandong Provincial Qianfoshan Hospital, Shandong Second Medical University, Jinan 250012, PR China
1 shared publicationChunyuan Zhao
Department of Immunology, Key Laboratory for Experimental Teratology of the Chinese Ministry of Education, School of Basic Medical Science, Cheeloo College of Medicine, Shandong University , Jinan, Shandong
1 shared publicationFei-Hua Chen
Department of General Surgery, First People’s Hospital of Hangzhou Lin’an District, Hangzhou, China
1 shared publication
Latest Publications
- Open Access
- 24 September 2026
- Published by Termedia Sp. z.o.o. in Central European Journal of Immunology
Calming the inflammatory storm: 4-methylcatechol ameliorates DSS-induced colitis by suppressing the NLRP3 inflammasome signaling pathway
Introduction: The natural polyphenol metabolite 4-methylcatechol (4-MC) has demonstrated anti-inflammatory and antioxidant properties. However, its effectiveness in ulcerative colitis (UC) and the molecular mechanisms involved are still poorly understood. This study aimed to evaluate the protective effects of 4-MC in a dextran sulfate sodium (DSS)-induced murine colitis model, with a particular focus on its potential role in modulating the NLRP3 inflammasome pathway. Material and Methods: Colitis was induced in mice by administering 5% DSS in drinking water. Mice were divided into the Control, Model (DSS), Model + sulfasalazine (SASP), and Model + 4-MC groups. Disease severity was monitored through body weight changes, disease activity index (DAI) scoring, and colon length measurement. Histological injury was evaluated by H&E and TUNEL staining. Intestinal barrier integrity was examined via immunofluorescence staining of occludin and E-cadherin. Inflammatory markers (TNF-, IL-6), myeloperoxidase (MPO) activity, oxidative stress markers (SOD, MDA, GSH), and key proteins in the NF-B and NLRP3 pathways were measured by ELISA, biochemical kits, Western blot and immunofluorescence. Results: 4-MC treatment significantly ameliorated the disease manifestations of DSS-induced colitis, including weight loss, increased DAI, and colon shortening. It attenuated colonic histopathological damage, reduced apoptosis, and increased the levels of the tight junction proteins occludin and E-cadherin. Furthermore, 4-MC suppressed the inflammatory response by decreasing TNF-, IL-6, and MPO levels. Mechanistically, 4-MC inhibited the activation of the NF-B pathway, alleviated oxidative stress, and suppressed the NLRP3 inflammasome pathway. Conclusions: 4-MC may protect against DSS-induced colitis by enhancing intestinal barrier function, attenuating inflammatory and oxidative stress responses, and suppressing NLRP3 inflammasome activation.
- 24 September 2026
- Published by Termedia Sp. z.o.o. in Central European Journal of Immunology
Open AccessCalming the inflammatory storm: 4-methylcatechol ameliorates DSS-induced colitis by suppressing the NLRP3 inflammasome signaling pathway
Introduction: The natural polyphenol metabolite 4-methylcatechol (4-MC) has demonstrated anti-inflammatory and antioxidant properties. However, its effectiveness in ulcerative colitis (UC) and the molecular mechanisms involved are still poorly understood. This study aimed to evaluate the protective effects of 4-MC in a dextran sulfate sodium (DSS)-induced murine colitis model, with a particular focus on its potential role in modulating the NLRP3 inflammasome pathway. Material and Methods: Colitis was induced in mice by administering 5% DSS in drinking water. Mice were divided into the Control, Model (DSS), Model + sulfasalazine (SASP), and Model + 4-MC groups. Disease severity was monitored through body weight changes, disease activity index (DAI) scoring, and colon length measurement. Histological injury was evaluated by H&E and TUNEL staining. Intestinal barrier integrity was examined via immunofluorescence staining of occludin and E-cadherin. Inflammatory markers (TNF-, IL-6), myeloperoxidase (MPO) activity, oxidative stress markers (SOD, MDA, GSH), and key proteins in the NF-B and NLRP3 pathways were measured by ELISA, biochemical kits, Western blot and immunofluorescence. Results: 4-MC treatment significantly ameliorated the disease manifestations of DSS-induced colitis, including weight loss, increased DAI, and colon shortening. It attenuated colonic histopathological damage, reduced apoptosis, and increased the levels of the tight junction proteins occludin and E-cadherin. Furthermore, 4-MC suppressed the inflammatory response by decreasing TNF-, IL-6, and MPO levels. Mechanistically, 4-MC inhibited the activation of the NF-B pathway, alleviated oxidative stress, and suppressed the NLRP3 inflammasome pathway. Conclusions: 4-MC may protect against DSS-induced colitis by enhancing intestinal barrier function, attenuating inflammatory and oxidative stress responses, and suppressing NLRP3 inflammasome activation.
- 21 December 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 146, 113855
Regulation of macrophage polarization and pyroptosis by 4-methylcatechol alleviates collagen-induced arthritis via Nrf2/HO-1 and NF-κB/NLRP3 signaling pathways
- 21 December 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 146, 113855
Regulation of macrophage polarization and pyroptosis by 4-methylcatechol alleviates collagen-induced arthritis via Nrf2/HO-1 and NF-κB/NLRP3 signaling pathways
- 10 November 2023
- Published by Springer Nature in Chinese Journal of Integrative Medicine
- Vol. 30 (4) , 339-347
Safflower Yellow Inhibits Progression of Hepatocellular Carcinoma by Modulating Immunological Tolerance via FAK Pathway
Objective To explore the anti-tumor effect of safflower yellow (SY) against hepatocellular carcinoma (HCC) and the underlying potential mechanism. Methods An in vitro model was established by mixing Luc-Hepa1-6 cells and CD3+CD8+ T cells, followed by adding programmed cell death protein 1 (PD-1) antibody (Anti-mPD-1) with or without SY. The apoptosis was detected by flow cytometry and the level of inflammatory cytokines was determined by enzyme-linked immunosorbent assay. The protein levels of programmed cell death 1 ligand 1 (PD-L1), chemokine ligand (CCL5), C-X-C motif chemokine ligand 10 (CXCL10) were measured by Western blot. An in situ animal model was established in mice followed by treatment with anti-mPD-1 with or without SY. Bioluminescence imaging was monitored with an AniView 100 imaging system. To establish the FAK-overexpressed Luc-Hepa1-6 cells, cells were transfected with adenovirus containing pcDNA3.1-FAK for 48 h. Results The fluorescence intensity, apoptotic rate, release of inflammatory cytokines, and CCL5/CXCL10 secretion were dramatically facilitated by anti-mPD-1 (PPP+CD8+ T cells, facilitated release of inflammatory cytokines, inactivated PD-1/PD-L1 axis, and increased CCL5/CXCL10 secretion were observed in Anti-mPD-1 treated mice (PPP+CD8+ T cells were abolished by FAK overexpression (P<0.01). Conclusion SY inhibited the progression of HCC by mediating immunological tolerance through inhibiting FAK.
- 10 November 2023
- Published by Springer Nature in Chinese Journal of Integrative Medicine
- Vol. 30 (4) , 339-347
Safflower Yellow Inhibits Progression of Hepatocellular Carcinoma by Modulating Immunological Tolerance via FAK Pathway
Objective To explore the anti-tumor effect of safflower yellow (SY) against hepatocellular carcinoma (HCC) and the underlying potential mechanism. Methods An in vitro model was established by mixing Luc-Hepa1-6 cells and CD3+CD8+ T cells, followed by adding programmed cell death protein 1 (PD-1) antibody (Anti-mPD-1) with or without SY. The apoptosis was detected by flow cytometry and the level of inflammatory cytokines was determined by enzyme-linked immunosorbent assay. The protein levels of programmed cell death 1 ligand 1 (PD-L1), chemokine ligand (CCL5), C-X-C motif chemokine ligand 10 (CXCL10) were measured by Western blot. An in situ animal model was established in mice followed by treatment with anti-mPD-1 with or without SY. Bioluminescence imaging was monitored with an AniView 100 imaging system. To establish the FAK-overexpressed Luc-Hepa1-6 cells, cells were transfected with adenovirus containing pcDNA3.1-FAK for 48 h. Results The fluorescence intensity, apoptotic rate, release of inflammatory cytokines, and CCL5/CXCL10 secretion were dramatically facilitated by anti-mPD-1 (PPP+CD8+ T cells, facilitated release of inflammatory cytokines, inactivated PD-1/PD-L1 axis, and increased CCL5/CXCL10 secretion were observed in Anti-mPD-1 treated mice (PPP+CD8+ T cells were abolished by FAK overexpression (P<0.01). Conclusion SY inhibited the progression of HCC by mediating immunological tolerance through inhibiting FAK.
- 1 September 2022
- Published by American Scientific Publishers in Journal of Biomedical Nanotechnology
- Vol. 18 (9) , 2145-2153
USP36 Facilitates the Progression of Hepatocellular Carcinoma by Upregulating Myc
Objective: Our study will explore the function and regulatory mechanism of USP36 in hepatocellular carcinoma (HCC). Methods: USP36-overexpressed and USP36-knockdown cells were established. The USP36 and Myc level were checked by Western blotting and the cell viability was checked by the MTT method. The apoptotic rate was checked by flow cytometry, while the migration was detected by the Transwell assay. A xenograft model was constructed in nude mice to explore the function of USP36 in HCC. USP36-overexpressed and USP-knockdown cells were constructed by transfecting pcDNA3.1-USP36 and siRNA-USP36 (si-USP36), respectively. Myc-overexpressed cells were constructed by transfecting pcDNA3.1-Myc. Results: Significantly declined cell viability, increased apoptotic rate, elevated number of migrated cells, downregulated Myc, and repressed tumor growth were observed in USP36-knockdown HepG2 and HUH7 cells, while opposite results were observed in USP36-overexpressed HepG2 and HUH7 cells. The expression level of Myc was positively regulated by USP36. However, the USP36 level was not regulated by Myc. Lastly, the declined cell viability, increased apoptotic rate, and elevated number of migrated cells in USP36-knockdown HepG2 cells were dramatically abrogated by the overexpression of Myc. Conclusion: USP36 facilitated the progression of hepatocellular carcinoma by upregulating Myc.
- 1 September 2022
- Published by American Scientific Publishers in Journal of Biomedical Nanotechnology
- Vol. 18 (9) , 2145-2153
USP36 Facilitates the Progression of Hepatocellular Carcinoma by Upregulating Myc
Objective: Our study will explore the function and regulatory mechanism of USP36 in hepatocellular carcinoma (HCC). Methods: USP36-overexpressed and USP36-knockdown cells were established. The USP36 and Myc level were checked by Western blotting and the cell viability was checked by the MTT method. The apoptotic rate was checked by flow cytometry, while the migration was detected by the Transwell assay. A xenograft model was constructed in nude mice to explore the function of USP36 in HCC. USP36-overexpressed and USP-knockdown cells were constructed by transfecting pcDNA3.1-USP36 and siRNA-USP36 (si-USP36), respectively. Myc-overexpressed cells were constructed by transfecting pcDNA3.1-Myc. Results: Significantly declined cell viability, increased apoptotic rate, elevated number of migrated cells, downregulated Myc, and repressed tumor growth were observed in USP36-knockdown HepG2 and HUH7 cells, while opposite results were observed in USP36-overexpressed HepG2 and HUH7 cells. The expression level of Myc was positively regulated by USP36. However, the USP36 level was not regulated by Myc. Lastly, the declined cell viability, increased apoptotic rate, and elevated number of migrated cells in USP36-knockdown HepG2 cells were dramatically abrogated by the overexpression of Myc. Conclusion: USP36 facilitated the progression of hepatocellular carcinoma by upregulating Myc.
- 1 June 2021
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 206 (11) , 2692-2699
Galectin-9 Targets NLRP3 for Autophagic Degradation to Limit Inflammation
NOD-, LRR-, and pyrin domain–containing protein 3 (NLRP3) inflammasome has been implicated in a variety of inflammatory disorders, and its activation should be tightly controlled to avoid detrimental effects. NLRP3 protein expression is considered as the rate-limiting step for NLRP3 inflammasome activation. In this study, we show that galectin-9 (encoded by lgals9) attenuated NLRP3 inflammasome activation by promoting the protein degradation of NLRP3 in primary peritoneal macrophages of C57BL/6J mice. Lgals9 deficiency enhances NLRP3 inflammasome activation and promotes NLRP3-dependent inflammation in C57BL/6J mice in vivo. Mechanistically, galectin-9 interacts with NLRP3, promotes the formation of NLRP3/p62 (an autophagic cargo receptor, also known as SQSTM1) complex, and thus facilitates p62-dependent autophagic degradation of NLRP3 in primary peritoneal macrophages of C57BL/6J mice and HEK293T cells. Therefore, we identify galectin-9 as an “eat-me” signal for selective autophagy of NLRP3 and uncover the potential roles of galectins in controlling host protein degradation. Furthermore, our work suggests galectin-9 as a priming therapeutic target for the diseases caused by improper NLRP3 inflammasome activation. Key Points Galectin-9 inhibits NLRP3 inflammasome activation by promoting NLRP3 degradation. Galectin-9 facilitates p62-dependent autophagic degradation of NLRP3.
- 1 June 2021
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 206 (11) , 2692-2699
Galectin-9 Targets NLRP3 for Autophagic Degradation to Limit Inflammation
NOD-, LRR-, and pyrin domain–containing protein 3 (NLRP3) inflammasome has been implicated in a variety of inflammatory disorders, and its activation should be tightly controlled to avoid detrimental effects. NLRP3 protein expression is considered as the rate-limiting step for NLRP3 inflammasome activation. In this study, we show that galectin-9 (encoded by lgals9) attenuated NLRP3 inflammasome activation by promoting the protein degradation of NLRP3 in primary peritoneal macrophages of C57BL/6J mice. Lgals9 deficiency enhances NLRP3 inflammasome activation and promotes NLRP3-dependent inflammation in C57BL/6J mice in vivo. Mechanistically, galectin-9 interacts with NLRP3, promotes the formation of NLRP3/p62 (an autophagic cargo receptor, also known as SQSTM1) complex, and thus facilitates p62-dependent autophagic degradation of NLRP3 in primary peritoneal macrophages of C57BL/6J mice and HEK293T cells. Therefore, we identify galectin-9 as an “eat-me” signal for selective autophagy of NLRP3 and uncover the potential roles of galectins in controlling host protein degradation. Furthermore, our work suggests galectin-9 as a priming therapeutic target for the diseases caused by improper NLRP3 inflammasome activation. Key Points Galectin-9 inhibits NLRP3 inflammasome activation by promoting NLRP3 degradation. Galectin-9 facilitates p62-dependent autophagic degradation of NLRP3.